Development of bozepinib-loaded nanocapsules for nose-to-brain delivery: preclinical evaluation in glioblastoma.

To develop and characterize bozepinib-loaded lipid-core nanocapsules (BZP-LNC) as a potential treatment for glioblastoma (GBM). Characterization of nanocapsules was performed by diameter, polydispersity index, Zeta potential, pH and encapsulation efficiency. GBM cell viability, cell cycle and Annexin/PI were evaluated after BZP-LNC treatment. Synergism between BZP-LNC and temozolomide (TMZ) was performed by CompuSyn software and confirmed and . BZP-LNC showed adequate particle sizes, positive Zeta potential, narrow size distribution and high encapsulation efficiency. BZP-LNC reduces GBM growth by inducing apoptosis. BZP-LNC and TMZ showed synergistic effect and reduced the glioma growth by approximately 81%. The present study provides proof-of-principle insights for the combination of these drugs for GBM treatment.